Cargando…

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors

PURPOSE: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. PATIENTS AND METHODS: In part 1 of this phase Ib study, 24 patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wesolowski, Robert, Sharma, Neelesh, Reebel, Laura, Rodal, Mary Beth, Peck, Alexandra, West, Brian L., Marimuthu, Adhirai, Severson, Paul, Karlin, David A., Dowlati, Afshin, Le, Mai H., Coussens, Lisa M., Rugo, Hope S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6589951/ https://www.ncbi.nlm.nih.gov/pubmed/31258629 http://dx.doi.org/10.1177/1758835919854238

Ejemplares similares

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
por: Piawah, Sorbarikor, et al.
Publicado: (2019)

Pexidartinib (PLX3397) through restoring hippocampal synaptic plasticity ameliorates social isolation-induced mood disorders
por: Wang, Laifa, et al.
Publicado: (2022)

Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis
por: Thongchot, Suyanee, et al.
Publicado: (2022)

Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature
por: Giustini, Nicholas, et al.
Publicado: (2018)

A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor
por: Rosenbaum, Evan, et al.
Publicado: (2019)

Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)
por: Luo, Jingtao, et al.
Publicado: (2022)

Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells
por: Okojie, Akhabue K., et al.
Publicado: (2023)

Depletion of microglia with PLX3397 attenuates MK-801-induced hyperactivity associated with regulating inflammation-related genes in the brain
por: Ni, Rong-Jun, et al.
Publicado: (2023)

Suppression of Microgliosis With the Colony-Stimulating Factor 1 Receptor Inhibitor PLX3397 Does Not Attenuate Memory Defects During Epileptogenesis in the Rat
por: Wyatt-Johnson, Season K., et al.
Publicado: (2021)

Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice
por: Son, Yeonghoon, et al.
Publicado: (2020)

Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease
por: Sosna, Justyna, et al.
Publicado: (2018)

Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2019)

3397 Genetic variants in gestational diabetes mellitus
por: Kothiyal, Prachi, et al.
Publicado: (2019)

Correction to: Pexidartinib: First Approval
por: Lamb, Yvette N.
Publicado: (2020)

Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development
por: Benner, Brooke, et al.
Publicado: (2020)

Results from Phase I Extension Study Assessing Pexidartinib Treatment in Six Cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
por: Tap, William D., et al.
Publicado: (2022)

Significant Sex Differences in the Efficacy of the CSF1R Inhibitor-PLX5622 on Rat Brain Microglia Elimination
por: Sharon, Aviv, et al.
Publicado: (2022)

Reply to Green and Hume: Nonmicroglia peripheral immune effects of short-term CSF1R inhibition with PLX5622
por: Lei, Fengyang, et al.
Publicado: (2021)

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors
por: Gelderblom, Hans, et al.
Publicado: (2020)

CSF1R inhibitor PLX5622 and environmental enrichment additively improve metabolic outcomes in middle-aged female mice
por: Ali, Seemaab, et al.
Publicado: (2020)

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects
por: Zahir, Hamim, et al.
Publicado: (2022)

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality
por: Zahir, Hamim, et al.
Publicado: (2022)

CSF1R inhibition with PLX5622 affects multiple immune cell compartments and induces tissue-specific metabolic effects in lean mice
por: Bosch, Angela J. T., et al.
Publicado: (2023)

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
por: Su, Xi, et al.
Publicado: (2021)

Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor
por: Monestime, Shanada, et al.
Publicado: (2020)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor
por: Yin, Ophelia, et al.
Publicado: (2021)

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors
por: Lewis, James H., et al.
Publicado: (2020)

Plx1 is required for chromosomal DNA replication under stressful conditions
por: Trenz, Kristina, et al.
Publicado: (2008)

Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors
por: Choi, Jaehyuk, et al.
Publicado: (2014)

Pexidartinib in the Management of Advanced Tenosynovial Giant Cell Tumor: Focus on Patient Selection and Special Considerations
por: Vaynrub, Anna, et al.
Publicado: (2022)

Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor
por: Bernthal, Nicholas M., et al.
Publicado: (2022)

Putting PLX5622 into perspective: microglia in central nervous system viral infection
por: Spiteri, Alanna G., et al.
Publicado: (2022)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

ZAK Inhibitor PLX4720 Promotes Extrusion of Transformed Cells via Cell Competition
por: Maruyama, Takeshi, et al.
Publicado: (2020)

PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism
por: Garbarino, Ombretta, et al.
Publicado: (2023)

Low-dose PLX5622 treatment prevents neuroinflammatory and neurocognitive sequelae after sepsis
por: Mein, Nils, et al.
Publicado: (2023)

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors
por: Yin, Ophelia, et al.
Publicado: (2020)

Identifying the Reactive Metabolites of Tyrosine Kinase Inhibitor Pexidartinib In Vitro Using LC–MS-Based Metabolomic Approaches
por: Qin, Xuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g7ku14dk8jvi3eu5jmh2956fmq